| 1 |
Ahmadi M, Emzhik M, Mosayebnia M. Nanoparticles labeled with gamma-emitting radioisotopes: an attractive approach for in vivo tracking using SPECT imaging. Drug Deliv Transl Res 2023. [PMID: 36811810 DOI: 10.1007/s13346-023-01291-1] [Reference Citation Analysis]
|
| 2 |
Forutan M, Hasani M, Hasani S, Salehi N, Sabbagh F. Liposome System for Encapsulation of Spirulina platensis Protein Hydrolysates: Controlled-Release in Simulated Gastrointestinal Conditions, Structural and Functional Properties. Materials (Basel) 2022;15. [PMID: 36500077 DOI: 10.3390/ma15238581] [Reference Citation Analysis]
|
| 3 |
Poletto G, Evangelista L, Venturini F, Gramegna F, Seno F, Moro S, Vettor R, Realdon N, Cecchin D. Nanoparticles and Radioisotopes: A Long Story in a Nutshell. Pharmaceutics 2022;14:2024. [DOI: 10.3390/pharmaceutics14102024] [Reference Citation Analysis]
|
| 4 |
Poletto G, Cecchin D, Bartoletti P, Venturini F, Realdon N, Evangelista L. Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review. Curr Issues Mol Biol 2022;44:3267-82. [PMID: 35892711 DOI: 10.3390/cimb44080225] [Reference Citation Analysis]
|
| 5 |
Wang Z, Li J, Lin G, He Z, Wang Y. Metal complex-based liposomes: Applications and prospects in cancer diagnostics and therapeutics. J Control Release 2022;348:1066-88. [PMID: 35718211 DOI: 10.1016/j.jconrel.2022.06.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 6 |
Skotland T, Iversen TG, Llorente A, Sandvig K. Biodistribution, pharmacokinetics and excretion studies of intravenously injected nanoparticles and extracellular vesicles: Possibilities and challenges. Adv Drug Deliv Rev 2022;186:114326. [PMID: 35588953 DOI: 10.1016/j.addr.2022.114326] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 7 |
Dennahy IS, Han Z, Maccuaig WM, Chalfant HM, Condacse A, Hagood JM, Claros-sorto JC, Razaq W, Holter-chakrabarty J, Squires R, Edil BH, Jain A, Mcnally LR. Nanotheranostics for Image-Guided Cancer Treatment. Pharmaceutics 2022;14:917. [DOI: 10.3390/pharmaceutics14050917] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Chen X, Niu W, Du Z, Zhang Y, Su D, Gao X. 64Cu radiolabeled nanomaterials for positron emission tomography (PET) imaging. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.02.070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Figueroa-pizano M, Carvajal-millan E. Nanovesicles for image-guided drug delivery. Systems of Nanovesicular Drug Delivery 2022. [DOI: 10.1016/b978-0-323-91864-0.00008-5] [Reference Citation Analysis]
|
| 10 |
Mignani S, Shi X, Guidolin K, Zheng G, Karpus A, Majoral JP. Clinical diagonal translation of nanoparticles: Case studies in dendrimer nanomedicine. J Control Release 2021;337:356-70. [PMID: 34311026 DOI: 10.1016/j.jconrel.2021.07.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 11 |
Chan HHL, Haerle SK, Daly MJ, Zheng J, Philp L, Ferrari M, Douglas CM, Irish JC. An integrated augmented reality surgical navigation platform using multi-modality imaging for guidance. PLoS One 2021;16:e0250558. [PMID: 33930063 DOI: 10.1371/journal.pone.0250558] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 12 |
Pellico J, Gawne PJ, T M de Rosales R. Radiolabelling of nanomaterials for medical imaging and therapy. Chem Soc Rev 2021;50:3355-423. [PMID: 33491714 DOI: 10.1039/d0cs00384k] [Cited by in Crossref: 50] [Cited by in F6Publishing: 60] [Article Influence: 25.0] [Reference Citation Analysis]
|
| 13 |
Izci M, Maksoudian C, Manshian BB, Soenen SJ. The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors. Chem Rev 2021;121:1746-803. [PMID: 33445874 DOI: 10.1021/acs.chemrev.0c00779] [Cited by in Crossref: 89] [Cited by in F6Publishing: 105] [Article Influence: 44.5] [Reference Citation Analysis]
|
| 14 |
Mi P, Miyata K, Kataoka K, Cabral H. Clinical Translation of Self‐Assembled Cancer Nanomedicines. Adv Therap 2021;4:2000159. [DOI: 10.1002/adtp.202000159] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 15 |
Ullah R, Wazir J, Khan FU, Diallo MT, Ihsan AU, Mikrani R, Aquib M, Zhou X. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines. AAPS PharmSciTech 2020;21:132. [PMID: 32409932 DOI: 10.1208/s12249-020-01691-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 16 |
Gabizon AA, de Rosales RTM, La-Beck NM. Translational considerations in nanomedicine: The oncology perspective. Adv Drug Deliv Rev 2020;158:140-57. [PMID: 32526450 DOI: 10.1016/j.addr.2020.05.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 17 |
Ng TSC, Garlin MA, Weissleder R, Miller MA. Improving nanotherapy delivery and action through image-guided systems pharmacology. Theranostics 2020;10:968-97. [PMID: 31938046 DOI: 10.7150/thno.37215] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 18 |
Man F, Gawne PJ, T M de Rosales R. Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine. Adv Drug Deliv Rev 2019;143:134-60. [PMID: 31170428 DOI: 10.1016/j.addr.2019.05.012] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 13.8] [Reference Citation Analysis]
|
| 19 |
Man F, Lammers T, T M de Rosales R. Imaging Nanomedicine-Based Drug Delivery: a Review of Clinical Studies. Mol Imaging Biol 2018;20:683-95. [PMID: 30084044 DOI: 10.1007/s11307-018-1255-2] [Cited by in Crossref: 63] [Cited by in F6Publishing: 71] [Article Influence: 15.8] [Reference Citation Analysis]
|
| 20 |
Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, Molnár I, Wickham TJ, Reynolds J, Campbell K, Hendriks BS, Adiwijaya BS, Geretti E, Moyo V, Miller KD. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. Br J Cancer 2018;119:1086-93. [PMID: 30361524 DOI: 10.1038/s41416-018-0235-2] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 9.6] [Reference Citation Analysis]
|
| 21 |
Ahmedova A, Todorov B, Burdzhiev N, Goze C. Copper radiopharmaceuticals for theranostic applications. European Journal of Medicinal Chemistry 2018;157:1406-25. [DOI: 10.1016/j.ejmech.2018.08.051] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 22 |
Yang Y, Zhao X, Xing Y, Yu T, Zhang J, Wang J. Preclinical evaluation of 99mTc direct labeling ZHER2:V2 for HER2 positive tumors imaging. Oncol Lett 2018;16:5361-6. [PMID: 30250607 DOI: 10.3892/ol.2018.9279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 23 |
Lee H, Gaddy D, Ventura M, Bernards N, de Souza R, Kirpotin D, Wickham T, Fitzgerald J, Zheng J, Hendriks BS. Companion Diagnostic 64Cu-Liposome Positron Emission Tomography Enables Characterization of Drug Delivery to Tumors and Predicts Response to Cancer Nanomedicines. Theranostics 2018;8:2300-12. [PMID: 29721081 DOI: 10.7150/thno.21670] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 24 |
Lamichhane N, Udayakumar TS, D'Souza WD, Simone CB 2nd, Raghavan SR, Polf J, Mahmood J. Liposomes: Clinical Applications and Potential for Image-Guided Drug Delivery. Molecules 2018;23:E288. [PMID: 29385755 DOI: 10.3390/molecules23020288] [Cited by in Crossref: 137] [Cited by in F6Publishing: 144] [Article Influence: 27.4] [Reference Citation Analysis]
|
| 25 |
Huang L. Preface. Handbook of Nanomaterials for Cancer Theranostics 2018. [DOI: 10.1016/b978-0-12-813339-2.10000-3] [Reference Citation Analysis]
|
| 26 |
Cheung C, Al-jamal WT. Liposomes-Based Nanoparticles for Cancer Therapy and Bioimaging. Nanooncology 2018. [DOI: 10.1007/978-3-319-89878-0_2] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 27 |
Blocker SJ, Douglas KA, Polin LA, Lee H, Hendriks BS, Lalo E, Chen W, Shields AF. Liposomal 64Cu-PET Imaging of Anti-VEGF Drug Effects on Liposomal Delivery to Colon Cancer Xenografts. Theranostics 2017;7:4229-39. [PMID: 29158822 DOI: 10.7150/thno.21688] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 28 |
Dearling JL, Packard AB. Molecular imaging in nanomedicine – A developmental tool and a clinical necessity. Journal of Controlled Release 2017;261:23-30. [DOI: 10.1016/j.jconrel.2017.06.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 29 |
Pool M, de Boer HR, Hooge MNL, van Vugt MATM, de Vries EGE. Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine. Theranostics 2017;7:2111-33. [PMID: 28638489 DOI: 10.7150/thno.17934] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 30 |
Lamichhane N, Dewkar GK, Sundaresan G, Mahon RN, Zweit J. [18F]-Fluorinated Carboplatin and [111In]-Liposome for Image-Guided Drug Delivery. Int J Mol Sci 2017;18:E1079. [PMID: 28524076 DOI: 10.3390/ijms18051079] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 31 |
Lee H, Shields AF, Siegel BA, Miller KD, Krop I, Ma CX, LoRusso PM, Munster PN, Campbell K, Gaddy DF, Leonard SC, Geretti E, Blocker SJ, Kirpotin DB, Moyo V, Wickham TJ, Hendriks BS. 64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer. Clin Cancer Res 2017;23:4190-202. [PMID: 28298546 DOI: 10.1158/1078-0432.CCR-16-3193] [Cited by in Crossref: 203] [Cited by in F6Publishing: 221] [Article Influence: 33.8] [Reference Citation Analysis]
|
| 32 |
Tagami T, Ozeki T. Recent Trends in Clinical Trials Related to Carrier-Based Drugs. J Pharm Sci 2017;106:2219-26. [PMID: 28259767 DOI: 10.1016/j.xphs.2017.02.026] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 33 |
Smith BR, Gambhir SS. Nanomaterials for In Vivo Imaging. Chem Rev 2017;117:901-86. [PMID: 28045253 DOI: 10.1021/acs.chemrev.6b00073] [Cited by in Crossref: 687] [Cited by in F6Publishing: 715] [Article Influence: 114.5] [Reference Citation Analysis]
|
| 34 |
Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 2017;17:20-37. [PMID: 27834398 DOI: 10.1038/nrc.2016.108] [Cited by in Crossref: 3393] [Cited by in F6Publishing: 3449] [Article Influence: 565.5] [Reference Citation Analysis]
|
| 35 |
Chakravarty R, Chen F, Dash A, Cai W. Theranostic Nanoplatforms for PET Image-Guided Drug Delivery. Design and Applications of Nanoparticles in Biomedical Imaging 2017. [DOI: 10.1007/978-3-319-42169-8_12] [Reference Citation Analysis]
|
| 36 |
Edmonds S, Volpe A, Shmeeda H, Parente-Pereira AC, Radia R, Baguña-Torres J, Szanda I, Severin GW, Livieratos L, Blower PJ, Maher J, Fruhwirth GO, Gabizon A, T M de Rosales R. Exploiting the Metal-Chelating Properties of the Drug Cargo for In Vivo Positron Emission Tomography Imaging of Liposomal Nanomedicines. ACS Nano 2016;10:10294-307. [PMID: 27781436 DOI: 10.1021/acsnano.6b05935] [Cited by in Crossref: 58] [Cited by in F6Publishing: 64] [Article Influence: 8.3] [Reference Citation Analysis]
|
| 37 |
Ekdawi SN, Jaffray DA, Allen C. Nanomedicine and tumor heterogeneity: Concept and complex reality. Nano Today 2016;11:402-14. [DOI: 10.1016/j.nantod.2016.06.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 38 |
Hervella P, Parra E, Needham D. Encapsulation and retention of chelated-copper inside hydrophobic nanoparticles: Liquid cored nanoparticles show better retention than a solid core formulation. European Journal of Pharmaceutics and Biopharmaceutics 2016;102:64-76. [DOI: 10.1016/j.ejpb.2016.02.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 39 |
Henriksen JR, Petersen AL, Hansen AE, Frankær CG, Harris P, Elema DR, Kristensen AT, Kjær A, Andresen TL. Remote Loading of 64 Cu 2+ into Liposomes without the Use of Ion Transport Enhancers. ACS Appl Mater Interfaces 2015;7:22796-806. [DOI: 10.1021/acsami.5b04612] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 40 |
Spence T, De Souza R, Dou Y, Stapleton S, Reilly RM, Allen C. Integration of imaging into clinical practice to assess the delivery and performance of macromolecular and nanotechnology-based oncology therapies. J Control Release 2015;219:295-312. [PMID: 26403800 DOI: 10.1016/j.jconrel.2015.09.036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 41 |
Gaddy DF, Lee H, Zheng J, Jaffray DA, Wickham TJ, Hendriks BS. Whole-body organ-level and kidney micro-dosimetric evaluations of (64)Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin ((64)Cu-MM-302) in rodents and primates. EJNMMI Res 2015;5:24. [PMID: 25918676 DOI: 10.1186/s13550-015-0096-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
|
